| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Corrigendum. Therapeutic advances in psychopharmacology. vol 5. issue 6. 2016-02-04. PMID:26836398. |
a 6-week, double-blind, placebo- and haloperidol-controlled, phase ii study of lurasidone in patients with acute schizophrenia. |
2016-02-04 |
2023-08-13 |
Not clear |
| Steven G Potkin, Tatsuya Kimura, John Guarin. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Therapeutic advances in psychopharmacology. vol 5. issue 6. 2016-02-02. PMID:26834965. |
a 6-week, double-blind, placebo- and haloperidol-controlled, phase ii study of lurasidone in patients with acute schizophrenia. |
2016-02-02 |
2023-08-13 |
Not clear |
| Steven G Potkin, Tatsuya Kimura, John Guarin. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Therapeutic advances in psychopharmacology. vol 5. issue 6. 2016-02-02. PMID:26834965. |
the objective of this study was to evaluate the short-term efficacy and safety of the atypical antipsychotic agent lurasidone in the treatment of schizophrenia. |
2016-02-02 |
2023-08-13 |
Not clear |
| Antony Loebel, Leslie Citrom. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych bulletin. vol 39. issue 5. 2016-01-12. PMID:26755968. |
lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. |
2016-01-12 |
2023-08-13 |
Not clear |
| Antony Loebel, Leslie Citrom. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych bulletin. vol 39. issue 5. 2016-01-12. PMID:26755968. |
lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the uk, and is also approved in the usa and canada for the treatment of major depressive episodes associated with bipolar i disorder as either a monotherapy or adjunctive therapy with lithium or valproate. |
2016-01-12 |
2023-08-13 |
Not clear |
| Antony Loebel, Leslie Citrom. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych bulletin. vol 39. issue 5. 2016-01-12. PMID:26755968. |
long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse. |
2016-01-12 |
2023-08-13 |
Not clear |
| Dawn Bruijnzeel, Mehdi Yazdanpanah, Uma Suryadevara, Rajiv Tando. Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert opinion on pharmacotherapy. vol 16. issue 10. 2015-11-23. PMID:26111577. |
lurasidone in the treatment of schizophrenia: a critical evaluation. |
2015-11-23 |
2023-08-13 |
Not clear |
| Dawn Bruijnzeel, Mehdi Yazdanpanah, Uma Suryadevara, Rajiv Tando. Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert opinion on pharmacotherapy. vol 16. issue 10. 2015-11-23. PMID:26111577. |
antipsychotic medications are the foundation of the pharmacological treatment of schizophrenia and lurasidone is the most recent of the 65 agents around the world to become available. |
2015-11-23 |
2023-08-13 |
Not clear |
| Mauro Giovanni Carta, Maria Francesca Moro, Antonio E Nardi, Joseph R Calabres. Potential use of lurasidone for the treatment of bipolar psychosis. Expert opinion on investigational drugs. vol 24. issue 4. 2015-11-13. PMID:25633339. |
lurasidone is one such sga, which is currently approved as a monotherapy for bipolar i depression (bpid) and as an add-on therapy for acute schizophrenia. |
2015-11-13 |
2023-08-13 |
Not clear |
| L Samalin, M Ben Gharbia, M Garnier, P-M Llorc. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 40. issue 6. 2015-09-21. PMID:25453735. |
[short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. |
2015-09-21 |
2023-08-13 |
Not clear |
| L Samalin, M Ben Gharbia, M Garnier, P-M Llorc. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 40. issue 6. 2015-09-21. PMID:25453735. |
lurasidone is a new second-generation antipsychotic approved in october 2010 by the food and drug administration and in march 2014 by the european medicines agency for the treatment of schizophrenia. |
2015-09-21 |
2023-08-13 |
Not clear |
| L Samalin, M Ben Gharbia, M Garnier, P-M Llorc. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 40. issue 6. 2015-09-21. PMID:25453735. |
lurasidone has demonstrated its efficacy in several short-term studies in acute schizophrenia with significantly reducing total scores of positive and negative syndrome scale (panss) and brief psychiatric rating scale (bprs) compared with placebo. |
2015-09-21 |
2023-08-13 |
Not clear |
| L Samalin, M Ben Gharbia, M Garnier, P-M Llorc. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 40. issue 6. 2015-09-21. PMID:25453735. |
post hoc analysis of four pooled short-term studies showed significantly better effects on improving depressive symptoms associated with schizophrenia in patients treated with lurasidone as compared to patients treated with placebo. |
2015-09-21 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Josephine B Cucchiaro, Yongcai Mao, Andrei A Pikalov, Antony D Loebe. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS spectrums. vol 20. issue 2. 2015-09-15. PMID:24955752. |
lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. |
2015-09-15 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Josephine B Cucchiaro, Yongcai Mao, Andrei A Pikalov, Antony D Loebe. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS spectrums. vol 20. issue 2. 2015-09-15. PMID:24955752. |
lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar i disorder. |
2015-09-15 |
2023-08-13 |
Not clear |
| Henry A Nasrallah, Josephine B Cucchiaro, Yongcai Mao, Andrei A Pikalov, Antony D Loebe. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS spectrums. vol 20. issue 2. 2015-09-15. PMID:24955752. |
this post hoc analysis evaluated the effect of lurasidone on depressive symptoms in patients with schizophrenia. |
2015-09-15 |
2023-08-13 |
Not clear |
| George Awad, Mariam Hassan, Antony Loebel, Jay Hsu, Andrei Pikalov, Krithika Rajagopala. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC psychiatry. vol 14. 2015-09-02. PMID:24559217. |
health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. |
2015-09-02 |
2023-08-12 |
Not clear |
| George Awad, Mariam Hassan, Antony Loebel, Jay Hsu, Andrei Pikalov, Krithika Rajagopala. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC psychiatry. vol 14. 2015-09-02. PMID:24559217. |
this analysis evaluated hrqol changes among patients with schizophrenia switched from their current antipsychotic to lurasidone. |
2015-09-02 |
2023-08-12 |
Not clear |
| Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge, Thilo Deckersbac. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric disease and treatment. vol 11. 2015-08-28. PMID:26316760. |
safety data drawn from these studies, as well as a more extensive body of schizophrenia research, indicate that in comparison with other atypical antipsychotics, treatment with lurasidone is less likely to result in metabolic side effects such as weight gain or disturbances of serum glucose or lipid levels. |
2015-08-28 |
2023-08-13 |
Not clear |
| Philip D Harve. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric disease and treatment. vol 11. 2015-05-21. PMID:25995636. |
the clinical utility of lurasidone in schizophrenia: patient considerations. |
2015-05-21 |
2023-08-13 |
Not clear |